The significant revenue growth and raised guidance suggest strong commercial momentum. The upcoming clinical catalysts, particularly the Q2 2026 topline data for volixibat in PSC, could be major value drivers. The increased cash position provides runway for pipeline advancement.
Price Chart
Executive Summary
Mirum Pharmaceuticals reported strong 2025 financial results with $521.3 million in net product sales, representing 55% year-over-year growth. The company raised its 2026 guidance to $630-$650 million in global net product sales and highlighted four upcoming clinical catalysts, including topline data for volixibat in PSC expected in Q2 2026.
Key Financial Metrics
Key Facts
- 2025 net product sales of $521.3 million, up 55% YoY from $336.4 million in 2024
- 2026 guidance raised to $630-$650 million in global net product sales
- LIVMARLI net sales reached $360.0 million in 2025, up 69% YoY
- Bile Acid Medicines net sales reached $161.3 million in 2025, up 31% YoY
- Unrestricted cash, cash equivalents and investments increased to $391.4 million as of December 31, 2025
- Four potentially registrational readouts expected over the next 18 months, starting with volixibat VISTAS study in PSC in Q2 2026
Financial Impact
2025 revenue of $521.3 million (55% YoY growth) with 2026 guidance of $630-$650 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LIVMARLI | $360.0M | +69.0% |
| Bile Acid Medicines | $161.3M | +31.0% |
Risk Factors
- Increased operating expenses from $424.5 million in 2024 to $543.4 million in 2025
- Continued net losses, though improving from $87.9 million in 2024 to $23.4 million in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000010 |
| Document: mirm-20260225.htm | 0001759425-26-000010 |
| Document: 0001759425-26-000010-index-headers.html | 0001759425-26-000010 |
| Document: 0001759425-26-000010-index.html | 0001759425-26-000010 |
| Document: 0001759425-26-000010.txt | 0001759425-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $102.24 $98.82 | ▼ −3.35% | ▼ −1.39% | $82.58 (−19.23%) |
Aug 12, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▲ +1.66% | ▲ +3.55% | $82.58 (−16.56%) |
Aug 11, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▼ −1.66% | ▼ −3.55% | $82.58 (+16.56%) |
Aug 10, 2026 7w ago | 144 | $98.23 $98.30 | ▲ +0.07% | ▲ +1.13% | $82.58 (−15.93%) |
Aug 5, 2026 8w ago | 8-K | $94.12 $100.63 | ▲ +6.92% | ▲ +6.32% | $82.58 (−12.26%) |
Jul 8, 2026 12w ago | Insider Cluster | $128.57 $105.79 | ▼ −17.72% | ▼ −20.99% | $82.58 (−35.77%) |
Jun 11, 2026 16w ago | Institutional Cluster | $99.54 $127.70 | ▲ +28.29% | ▲ +26.40% | $82.58 (−17.04%) |
Jun 10, 2026 16w ago | Insider Cluster | $94.00 $127.70 | ▲ +35.85% | ▲ +32.23% | $82.58 (−12.15%) |
Jun 2, 2026 17w ago | Insider Cluster | $91.84 $125.59 | ▲ +36.76% | ▲ +37.76% | $82.58 (−10.08%) |
Jun 1, 2026 17w ago | 144 | $92.17 $120.46 | ▲ +30.69% | ▲ +32.26% | $82.58 (−10.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access